FOLD
FY2026 EPS Estimate
$0.36
FY2026E EPS$0.36
FY2027E EPS$0.64

Analyst Sentiment

Wall St. Consensus
Buy
24 analysts·High coverage
66
Score
16 Buy (67%)7 Hold (29%)1 Sell (4%)
Rating Breakdown
Strong Buy
00%
Buy
1667%
Hold
729%
Sell
14%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$13.00
-10.3%
Consensus
$14.50
+0.1%
Bull
$19.00
+31.1%
12-Month Target Range24 analysts
$13.00$14.50$19.00
Current $14.49Consensus
Current Price
$14.49
Upside to Consensus
$0.01

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+18.95%
EPS+79.44%
FY2028
Rev+22.20%
EPS+42.19%
FY2029
Rev+19.32%
EPS+49.45%
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029EFY2030E
Revenue Avg$754M$896M$1.10B$1.31B$1.47B
Low$752M$870M$1.09B$1.28B$1.44B
High$755M$916M$1.10B$1.34B$1.50B
EBITDA Avg$-205M$-244M$-298M$-356M$-400M
Low$-205M$-249M$-299M$-364M$-409M
High$-204M$-237M$-297M$-348M$-391M
EBIT Avg$-218M$-259M$-316M$-378M$-425M
Low$-218M$-265M$-318M$-387M$-435M
High$-217M$-251M$-315M$-369M$-415M
Net Income Avg$111M$197M$281M$419M$515M
Low$108M$187M$261M$407M$500M
High$113M$208M$300M$432M$531M
EPS Avg$0.36$0.64$0.91$1.36$1.67
Low$0.35$0.61$0.85$1.32$1.62
High$0.37$0.67$0.97$1.40$1.72
Analysts (Rev / EPS)3 / 15 / 33 / 21 / 12 / 1
Quarterly
MetricQ3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027
Revenue Avg$198M$211M$185M$200M$217M$271M
Low$198M$211M$185M$200M$217M$271M
High$198M$211M$185M$200M$217M$271M
EBITDA Avg$-54M$-57M$-50M$-54M$-59M$-74M
Low$-54M$-57M$-50M$-54M$-59M$-74M
High$-54M$-57M$-50M$-54M$-59M$-74M
EBIT Avg$-57M$-61M$-53M$-58M$-63M$-78M
Low$-57M$-61M$-53M$-58M$-63M$-78M
High$-57M$-61M$-53M$-58M$-63M$-78M
Net Income Avg$34M$38M$31M$41M$57M$135M
Low$34M$38M$31M$41M$57M$135M
High$34M$38M$31M$41M$57M$135M
EPS Avg$0.11$0.12$0.10$0.13$0.18$0.43
Low$0.11$0.12$0.10$0.13$0.18$0.43
High$0.11$0.12$0.10$0.13$0.18$0.43
Analysts (Rev / EPS)2 / 12 / 12 / 12 / 12 / 12 / 1

Earnings Surprises

Recent Analyst Actions

Jan 22, 2026Jefferies
Jefferies Downgrades Amicus Therapeutics (FOLD) to Hold
Target:$14.50
+1.0%from $14.35
Dec 19, 2025Cantor Fitzgerald
Amicus downgraded to Neutral from Overweight at Cantor Fitzgerald
Target:$14.50
+1.8%from $14.25
Sep 18, 2025Needham
Needham upgrades Amicus to Buy on reduced regulatory risk
Target:$14.00
+68.5%from $8.31
Oct 17, 2024Bank of America Securities
Amicus Therapeutics (FOLD) PT Raised to $15 at BofA Securities
Target:$15.00
+24.7%from $12.03
May 14, 2024Guggenheim
Amicus upgraded to Buy from Neutral at Guggenheim
Target:$13.00
+43.8%from $9.04
May 9, 2024Morgan Stanley
Amicus Therapeutics (FOLD) PT Lowered to $19 at Morgan Stanley
Target:$19.00
+100.4%from $9.48
Dec 19, 2023Morgan Stanley
Morgan Stanley Upgrades Amicus Therapeutics (FOLD) to Overweight
Target:$20.00
+58.0%from $12.66
May 10, 2021Goldman Sachs
Amicus Therapeutics (FOLD) PT Lowered to $14 at Goldman Sachs
Target:$14.00
+49.1%from $9.39
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.